Should you buy Mednax (MD) stock?
Find the latest MEDNAX, Inc. (MD) stock quote, history, news and other vital information to help you with your stock trading and investing.
Who buys MDMD stock?
Apr 03, 2022 · On average, they expect MEDNAX's stock price to reach $29.33 in the next year. This suggests a possible upside of 21.7% from the stock's current price. View analysts' price targets for MEDNAX or view top-rated stocks among Wall Street analysts .
Where can I buy shares of MD?
MD | Complete Mednax Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
What are analysts'target prices for Mednax's shares?
Real time MEDNAX (MD) stock price quote, stock graph, news & analysis.
Is MEDNAX a buy right now?
7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MEDNAX in the last twelve months. There are currently 1 sell rati...
How has MEDNAX's stock been impacted by Coronavirus?
MEDNAX's stock was trading at $13.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO)....
Are investors shorting MEDNAX?
MEDNAX saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 2,980,000 shares, an incre...
When is MEDNAX's next earnings date?
MEDNAX is scheduled to release its next quarterly earnings announcement on Friday, May 6th 2022. View our earnings forecast for MEDNAX .
How were MEDNAX's earnings last quarter?
MEDNAX, Inc. (NYSE:MD) announced its earnings results on Thursday, February, 17th. The company reported $0.50 earnings per share (EPS) for the quar...
What price target have analysts set for MD?
7 Wall Street analysts have issued 12 month price targets for MEDNAX's stock. Their forecasts range from $24.00 to $32.00. On average, they anticip...
Who are MEDNAX's key executives?
MEDNAX's management team includes the following people: Mark S. Ordan , Chief Executive Officer & Director Roger Mack Hinson , President ( Link...
What is Mark S. Ordan's approval rating as MEDNAX's CEO?
6 employees have rated MEDNAX CEO Mark S. Ordan on Glassdoor.com . Mark S. Ordan has an approval rating of 34% among MEDNAX's employees. This puts...
Who are some of MEDNAX's key competitors?
Some companies that are related to MEDNAX include Laboratory Co. of America (LH) , Quest Diagnostics (DGX) , DaVita (DVA) , Chemed (CHE) , R1...
About MEDNAX
MEDNAX (NYSE:MD) Frequently Asked Questions
MEDNAX, Inc. provides physician services including newborn, anesthesia, maternal-fetal, tele radiology, pediatric cardiology and other pediatric subspecialty care. The firm's solution include anesthesiology & pain management, prenatal, neonatal, pediatric, radiology, tele radiology, revenue cycle management and perioperative improvement consulting.
New York Stock Exchange
7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MEDNAX in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MEDNAX stock.
Environmental, Social, and Governance Rating
The Company provides neonatal, maternal fetal and other pediatric subspecialty physician services in 32 states and Puerto Rico.
Business Summary
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
Component Grades
The Company provides neonatal, maternal fetal and other pediatric subspecialty physician services in 32 states and Puerto Rico.
MD POWR Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
MD Stock Summary
Growth is the dimension where MD ranks best; there it ranks ahead of 98.91% of US stocks.
MD Valuation Summary
The price/operating cash flow metric for Mednax Inc is higher than 96.22% of stocks in our set with a positive cash flow.
MD Growth Metrics
MD's price/sales ratio is 1.5; this is 86.78% lower than that of the median Healthcare stock.
MD's Quality Factors
Its 3 year net cashflow from operations growth rate is now at -10.94%.
About CloudMD Software & Services
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
CloudMD Software & Services (CVE:DOC) Frequently Asked Questions
CloudMD Software & Services Inc., a healthcare technology company, provides SaaS based health technology solutions to medical clinics in North America.
Mountain Valley MD Holdings Announces Restricted Share Unit Plan, RSU Grant and Stock Option Grant
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CloudMD Software & Services in the last year. There are currently 2 buy ratings for the stock.
Stocks in play: Mountain Valley MD Holdings Inc
TORONTO, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Mountain Valley MD Holdings Inc.
Mountain Valley MD Holdings Completes Licensing Agreement With Red White and Bloom Brands Inc
Announced, further to its news release dated September 29, 2021, that Mountain Valley MD Inc. has entered ...
Mountain Valley MD Holdings Provides Business Update, Results of Shareholder Meeting
TORONTO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQX: MVMDF) (FRA: 20MP) is pleased to announce, further to its news release dated September 29, 2021, that Mountain Valley MD Inc.
Mountain Valley MD Holdings Announces Letter of Intent with Red White and Bloom Brands Inc
TORONTO, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQX: MVMDF) (FRA: 20MP) is pleased to provide a business update on key initiatives.
Mountain Valley MD Holdings Announces Voluntary Retraction of a Reported Data Set, No Material Change to Business Plan Anticipated
TORONTO, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (FRA: 20MP) is pleased to announce that Mountain Valley MD Inc. (“Mountain Valley”) has entered into a letter of intent (the “LOI”) to complete a licensing agreement with Red White & Bloom Brands Inc.
Mountain Valley MD Holdings Announces Annual Shareholder Meeting
TORONTO, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Mountain Valley MD Holdings Inc.
